GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » Cyclically Adjusted PB Ratio

Catalent (Catalent) Cyclically Adjusted PB Ratio : 3.90 (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Catalent Cyclically Adjusted PB Ratio?

As of today (2024-04-29), Catalent's current share price is $56.30. Catalent's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $14.43. Catalent's Cyclically Adjusted PB Ratio for today is 3.90.

The historical rank and industry rank for Catalent's Cyclically Adjusted PB Ratio or its related term are showing as below:

CTLT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.42   Med: 4.08   Max: 14.27
Current: 3.87

During the past years, Catalent's highest Cyclically Adjusted PB Ratio was 14.27. The lowest was 2.42. And the median was 4.08.

CTLT's Cyclically Adjusted PB Ratio is ranked worse than
77.42% of 651 companies
in the Drug Manufacturers industry
Industry Median: 1.76 vs CTLT: 3.87

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Catalent's adjusted book value per share data for the three months ended in Dec. 2023 was $20.408. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $14.43 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Catalent Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Catalent's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Cyclically Adjusted PB Ratio Chart

Catalent Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 9.91 3.31

Catalent Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.86 5.38 3.31 3.29 3.11

Competitive Comparison of Catalent's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Catalent's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalent's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Catalent's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Catalent's Cyclically Adjusted PB Ratio falls into.



Catalent Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Catalent's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=56.30/14.43
=3.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalent's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Catalent's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=20.408/129.4194*129.4194
=20.408

Current CPI (Dec. 2023) = 129.4194.

Catalent Quarterly Data

Book Value per Share CPI Adj_Book
201403 -3.410 99.695 -4.427
201406 -3.165 100.560 -4.073
201409 4.071 100.428 5.246
201412 3.984 99.070 5.204
201503 3.770 99.621 4.898
201506 5.100 100.684 6.556
201509 4.796 100.392 6.183
201512 4.878 99.792 6.326
201603 4.837 100.470 6.231
201606 5.099 101.688 6.490
201609 4.926 101.861 6.259
201612 4.713 101.863 5.988
201703 5.145 102.862 6.473
201706 5.786 103.349 7.246
201709 7.820 104.136 9.719
201712 7.542 104.011 9.384
201803 8.011 105.290 9.847
201806 8.145 106.317 9.915
201809 10.532 106.507 12.798
201812 10.733 105.998 13.105
201903 11.123 107.251 13.422
201906 11.542 108.070 13.822
201909 11.281 108.329 13.477
201912 11.738 108.420 14.011
202003 14.123 108.902 16.784
202006 17.807 108.767 21.188
202009 18.664 109.815 21.996
202012 20.315 109.897 23.924
202103 21.804 111.754 25.251
202106 22.962 114.631 25.924
202109 23.515 115.734 26.296
202112 25.034 117.630 27.543
202203 25.877 121.301 27.609
202206 26.676 125.017 27.615
202209 26.111 125.227 26.985
202212 27.289 125.222 28.204
202303 26.128 127.348 26.553
202306 25.578 128.729 25.715
202309 21.221 129.860 21.149
202312 20.408 129.419 20.408

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Catalent  (NYSE:CTLT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Catalent Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Catalent's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalent (Catalent) Business Description

Traded in Other Exchanges
Address
14 Schoolhouse Road, Somerset, NJ, USA, 08873
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Executives
David Mcerlane officer: Group President, Biologics C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Steven Barg director ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019
Michelle R Ryan director 214 PARK BLVD S, VENICE FL 34285
John J Greisch director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephanie Okey director C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Frank A Damelio director C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017
Aristippos Gennadios officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Thomas W Hawkeswood officer: Pres. Pharma Prod Delivery Div C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Patricia Hunt officer: Pres. Consumer Health Div C/O CATALENT, 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricky Hopson officer: VP, Chief Accounting Officer CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Lorenzo Carletti officer: SVP Global Ops Small Molecule C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricardo Pravda officer: SVP, Human Resources C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Alessandro Maselli officer: See remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Charles Lickfold officer: SVP, CIO C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Scott Gunther officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873

Catalent (Catalent) Headlines

From GuruFocus

Q3 2023 Catalent Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Catalent Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Catalent Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Catalent Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Catalent Inc Investor Presentation Transcript

By GuruFocus Research 01-22-2024

Catalent Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024